Eloxx Pharmaceuticals Inc (NQ: ELOX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 2.760 (4)
Ask (Size) 2.800 (6)
Prev. Close 3.820
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 2,752,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
From Eloxx Pharmaceuticals
Via GlobeNewswire
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
From Eloxx Pharmaceuticals
Via GlobeNewswire

Performance

More News

Read More
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
Via InvestorPlace
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 8/30
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
From Eloxx Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
This Small Cap Stock Surged Over 100%
Via MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.